CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 2, 2022-- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, August 9^th, 2022, at 4:30 pm ET to report its financial results for the second quarter of 2022.

Conference Call & Webcast Details

A live webcast of the conference call can be accessed in the Investors/ Media section of Infinity’s website at https://www.infi.com/ and will be available on Infinity's website for 30 days following the event.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005258/en/

Irina Koffler
LifeSci Advisors, LLC
646-970-4681
ikoffler@lifesciadvisors.com

Source: Infinity Pharmaceuticals, Inc.